Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1680062/000114036122028912/brhc10040384_10q.htm
February 2023
February 2023
January 2023
January 2023
January 2023
December 2022
November 2022
October 2022
October 2022
September 2022
Three Months Ended June 30,
|
||||||||||||||||
GAAP
|
Non-GAAP(1)
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(dollars in thousands, except EPS)
|
||||||||||||||||
Revenue
|
$
|
104,395
|
$
|
53,864
|
$
|
104,395
|
$
|
53,864
|
||||||||
Gross margin
|
42.3
|
%
|
40.2
|
%
|
42.4
|
%
|
40.5
|
%
|
||||||||
Income from operations
|
$
|
20,035
|
$
|
4,331
|
$
|
22,004
|
$
|
5,666
|
||||||||
Net income attributable to ACM Research, Inc.
|
$
|
12,236
|
$
|
6,567
|
$
|
14,628
|
$
|
4,119
|
||||||||
Basic EPS
|
$
|
0.21
|
$
|
0.11
|
$
|
0.25
|
$
|
0.07
|
||||||||
Diluted EPS (2)
|
$
|
0.18
|
$
|
0.10
|
$
|
0.22
|
$
|
0.06
|
Six Months Ended June 30,
|
||||||||||||||||
GAAP
|
Non-GAAP(1)
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(dollars in thousands, except EPS)
|
||||||||||||||||
Revenue
|
$
|
146,581
|
$
|
97,596
|
$
|
146,581
|
$
|
97,596
|
||||||||
Gross margin
|
43.6
|
%
|
40.7
|
%
|
43.7
|
%
|
40.9
|
%
|
||||||||
Income from operations
|
$
|
10,729
|
$
|
7,781
|
$
|
14,072
|
$
|
10,326
|
||||||||
Net income attributable to ACM Research, Inc.
|
$
|
6,450
|
$
|
12,037
|
$
|
14,074
|
$
|
11,846
|
||||||||
Basic EPS
|
$
|
0.11
|
$
|
0.21
|
$
|
0.24
|
$
|
0.21
|
||||||||
Diluted EPS (2)
|
$
|
0.10
|
$
|
0.19
|
$
|
0.21
|
$
|
0.18
|
(1) |
Reconciliations to U.S. generally accepted accounting principles (“GAAP”) financial measures from non-GAAP financial measures are presented below under “Reconciliation of GAAP to Non-GAAP Financial
Measures.” Non-GAAP financial measures exclude stock-based compensation and, with respect to net income (loss) attributable to ACM Research, Inc. and basic and diluted EPS, also exclude unrealized loss on trading securities.
|
(2) |
Prior period results have been adjusted to reflect the three-for-one stock split effected in the form of a stock dividend in March 2022.
|
• |
Shipments. Total shipments in the second quarter of 2022
were $112 million, versus $82 million in the second quarter of 2021. Shipments in the second quarter of 2022 included $24 million of tools that could not be delivered in the first quarter of 2022 due to the COVID-19-related restrictions
in Shanghai. Total shipments include deliveries for revenue in the quarter and deliveries of first tool systems awaiting customer acceptance for potential revenue in future quarters.
|
• |
Shipped Evaluation and Production Tools to U.S. Customer. Delivered
first Ultra C SAPS V 12-chamber cleaning tool for evaluation in June and shipped another tool in mid-July. ACM has expanded its U.S. services team to provide direct on-site support for the evaluation.
|
• |
Building Traction with China Operations of Semiconductor Manufacturers. During the first half of 2022, the Company delivered an Ultra C SAPS V 12-chamber cleaning tool for evaluation to the China fab of a global semiconductor manufacturer for evaluation, an Ultra ECP map copper
plating tool for evaluation to a regional Asia-based semiconductor manufacturer, and delivered an additional PR stripper tool and received additional orders from the China-based advanced packaging facility of a global Integrated Device
Manufacturer, (IDM).
|
• |
Introduction of New Post-CMP Cleaning Tool for Silicon and SiC Wafer Substrate Manufacturing. In July 2022, the Company announced the introduction of its new post-CMP cleaning tool. This is the Company’s first tool of its kind, serving as a cleaning step following the chemical mechanical planarization
(CMP) process used to manufacture high quality substrates. It is available in 6- and 8- inch configurations for silicon carbide (SiC), and 8- and 12- inch configurations for silicon wafer manufacturing. The tool is available in wet-in
dry-out (WIDO) and dry-in dry out (DIDO) configurations, with 2-, 4- and 6-chamber options to achieve maximum throughput of up to 60 wafers per hour (WPH).
|
• |
Appointment of Armanino LLP as Auditor for 2022. ACM
announced that Armanino LLP has been appointed as ACM’s independent registered public accounting firm to audit ACM’s consolidated financial statements and internal controls over financial reporting for the fiscal year ending December 31,
2022. Following completion of the 2022 audit of ACM’s consolidated financial statements and internal controls over financial reporting, ACM anticipates it will no longer be subject to delisting guidelines under the U.S. Holding Foreign
Companies Accountable Act (HFCAA).
|
• |
Revenue was $104.4 million, up 93.8%, reflecting an increase
in revenue from single wafer wet cleaning tools, new products groups, particularly ECP, Furnace and other technologies category. Revenue in the second quarter included $12.9 million of repeat shipments of tools that could not be delivered
in the first quarter due to COVID-19-related restrictions in Shanghai.
|
• |
Gross margin was 42.3%, up from 40.2%. Non-GAAP gross
margin, which excludes stock-based compensation, was 42.4%, up from 40.5%. Gross margin was within the range of 40% to 45% reflected in the Company’s long-term business model. The Company expects gross margin to vary from period to period
due to a variety of factors, such as sales volume and product mix.
|
• |
Operating expenses were $24.1 million, an increase of 39.0%.
Non-GAAP operating expenses, which exclude the effect of stock-based compensation, were $22.3 million, up 38.3%. Non-GAAP operating expenses as a percent of revenue decreased to 21.4% from 29.9%.
|
• |
Operating income was $20.0 million, up from $4.3 million. Non-GAAP operating income, which excludes the effect of stock-based compensation, was $22.0 million, up from $5.7 million.
|
• |
Unrealized loss on trading securities was $0.4 million. The
loss reflects the change in market value of the indirect investment by ACM Research (Shanghai), Inc. in the STAR Market IPO shares of Semiconductor Manufacturing International
Corporation (SMIC). The value is marked-to-market quarterly and is excluded from non-GAAP results.
|
• |
Income tax expense was $7.7 million, compared to $15,000.
The income tax expense for the period ending June 30, 2022 primarily resulted from an increase in the Company’s full year effective income tax rate. As a result of a change in Section 174 of the U.S. Internal Revenue Code of 1986 that
became effective on January 1, 2022, the effective tax rate for 2022 has increased, primarily due
to a new requirement to capitalize and amortize previously deductible research and experimental expenses.
|
• |
Net income attributable to ACM Research, Inc. was $12.2
million, compared to net income of $6.6 million. Non-GAAP net income attributable to ACM Research, Inc., which excludes the effect of stock-based compensation and unrealized loss on trading securities, was $14.6 million, as compared to
non-GAAP net income of $4.1 million.
|
• |
Net income per diluted share attributable to ACM Research, Inc. was $0.18, compared to $0.10. Non-GAAP net income per diluted share, which excludes the effect of stock-based compensation and unrealized loss on trading securities, was $0.22, compared to $0.06.
|
• |
Cash and cash equivalents were $323.7 million at June 30,
2022, versus $380.3 million at March 31, 2022. Cash and cash equivalents plus, restricted cash and deposits were $468.9 million at June 30, 2022, versus $533.1
million at March 31, 2022. The decrease in cash and cash equivalents for the three months ended June 30, 2022 is primarily attributable to cash used in operations of $33.6 million, and a $23.5 million decrease due to the effect of
exchange rate changes on cash and cash equivalents.
|
June 30, 2022
|
December 31, 2021
|
|||||||
(Unaudited)
|
||||||||
(In thousands, except for par value)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
323,716
|
$
|
562,548
|
||||
Restricted cash
|
628
|
519
|
||||||
Short-term time deposits
|
70,030
|
-
|
||||||
Trading securities
|
23,894
|
29,498
|
||||||
Accounts receivable
|
154,627
|
105,553
|
||||||
Income tax recoverable
|
1,521
|
1,082
|
||||||
Other receivables
|
16,208
|
18,979
|
||||||
Inventories
|
288,080
|
218,116
|
||||||
Advances to related party
|
3,073
|
2,383
|
||||||
Prepaid expenses
|
18,851
|
14,256
|
||||||
Total current assets
|
900,628
|
952,934
|
||||||
Property, plant and equipment, net
|
57,266
|
14,042
|
||||||
Land use right, net
|
9,092
|
9,667
|
||||||
Operating lease right-of-use assets, net
|
3,478
|
4,182
|
||||||
Intangible assets, net
|
661
|
477
|
||||||
Long-term time deposits
|
74,500
|
-
|
||||||
Deferred tax assets
|
10,767
|
13,166
|
||||||
Long-term investments
|
12,612
|
12,694
|
||||||
Other long-term assets
|
2,520
|
45,017
|
||||||
Total assets
|
1,071,524
|
1,052,179
|
||||||
Liabilities and Stockholders’ Equity
|
||||||||
Current liabilities:
|
||||||||
Short-term borrowings
|
4,898
|
9,591
|
||||||
Current portion of long-term borrowings
|
2,328
|
2,410
|
||||||
Related party accounts payable
|
9,062
|
7,899
|
||||||
Accounts payable
|
93,902
|
93,451
|
||||||
Advances from customers
|
94,421
|
52,824
|
||||||
Deferred revenue
|
2,950
|
3,180
|
||||||
Income taxes payable
|
2,032
|
254
|
||||||
FIN-48 payable
|
2,171
|
2,282
|
||||||
Other payables and accrued expenses
|
39,195
|
31,735
|
||||||
Current portion of operating lease liability
|
1,774
|
2,313
|
||||||
Total current liabilities
|
252,733
|
205,939
|
||||||
Long-term borrowings
|
20,642
|
22,957
|
||||||
Long-term operating lease liability
|
1,704
|
1,869
|
||||||
Deferred tax liability
|
1,237
|
1,302
|
||||||
Other long-term liabilities
|
8,063
|
8,447
|
||||||
Total liabilities
|
284,379
|
240,514
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Common stock – Class A
|
5
|
5
|
||||||
Common stock – Class B
|
1
|
1
|
||||||
Additional paid in capital
|
599,138
|
595,045
|
||||||
Accumulated surplus
|
70,182
|
63,732
|
||||||
Statutory surplus reserve
|
8,312
|
8,312
|
||||||
Accumulated other comprehensive income
|
(22,633
|
)
|
9,109
|
|||||
Total ACM Research, Inc. stockholders’ equity
|
655,005
|
676,204
|
||||||
Non-controlling interests
|
132,140
|
135,461
|
||||||
Total stockholders’ equity
|
787,145
|
811,665
|
||||||
Total liabilities and stockholders’ equity
|
$
|
1,071,524
|
$
|
1,052,179
|
Three Months Ended June 30,
|
Six Months Ended June 31,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
(Unaudited)
|
(Unaudited)
|
|||||||||||||||
( In thousands, except share and per share data)
|
( In thousands, except share and per share data)
|
|||||||||||||||
Revenue
|
$
|
104,395
|
$
|
53,864
|
$
|
146,581
|
$
|
97,596
|
||||||||
Cost of revenue
|
60,238
|
32,184
|
82,738
|
57,871
|
||||||||||||
Gross profit
|
44,157
|
21,680
|
63,843
|
39,725
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Sales and marketing
|
7,664
|
5,789
|
14,361
|
11,097
|
||||||||||||
Research and development
|
11,367
|
7,933
|
28,713
|
13,437
|
||||||||||||
General and administrative
|
5,091
|
3,627
|
10,040
|
7,410
|
||||||||||||
Total operating expenses, net
|
24,122
|
17,349
|
53,114
|
31,944
|
||||||||||||
Income from operations
|
20,035
|
4,331
|
10,729
|
7,781
|
||||||||||||
Interest income
|
2,144
|
31
|
3,949
|
80
|
||||||||||||
Interest expense
|
(306
|
)
|
(194
|
)
|
(567
|
)
|
(383
|
)
|
||||||||
Unrealized gain (loss) on trading securities
|
(423
|
)
|
3,783
|
(4,281
|
)
|
2,736
|
||||||||||
Other income (expense), net
|
2,505
|
(897
|
)
|
2,742
|
(428
|
)
|
||||||||||
Equity income in net income of affiliates
|
472
|
295
|
401
|
615
|
||||||||||||
Income before income taxes
|
24,427
|
7,349
|
12,973
|
10,401
|
||||||||||||
Income tax benefit (expense)
|
(7,679
|
)
|
(15
|
)
|
(3,668
|
)
|
2,755
|
|||||||||
Net income
|
16,748
|
7,334
|
9,305
|
13,156
|
||||||||||||
Less: Net income attributable to non-controlling interests
|
4,512
|
767
|
2,855
|
1,119
|
||||||||||||
Net income attributable to ACM Research, Inc.
|
$
|
12,236
|
$
|
6,567
|
$
|
6,450
|
$
|
12,037
|
||||||||
Comprehensive income:
|
||||||||||||||||
Net income
|
16,748
|
7,334
|
9,305
|
13,156
|
||||||||||||
Foreign currency translation adjustment
|
(40,372
|
)
|
3,000
|
(37,918
|
)
|
1,668
|
||||||||||
Comprehensive Income (loss)
|
(23,624
|
)
|
10,334
|
(28,613
|
)
|
14,824
|
||||||||||
Less: Comprehensive income (loss) attributable to non-controlling interests and redeemable non-controlling interests
|
(2,248
|
)
|
1,797
|
(3,321
|
)
|
1,714
|
||||||||||
Comprehensive income (loss) attributable to ACM Research, Inc.
|
$
|
(21,376
|
)
|
$
|
8,537
|
$
|
(25,292
|
)
|
$
|
13,110
|
||||||
Net income attributable to ACM Research, Inc. per common share:
|
||||||||||||||||
Basic
|
$
|
0.21
|
$
|
0.11
|
$
|
0.11
|
$
|
0.21
|
||||||||
Diluted
|
$
|
0.18
|
$
|
0.10
|
$
|
0.10
|
$
|
0.19
|
||||||||
Weighted average common shares outstanding used in computing per share amounts:
|
||||||||||||||||
Basic
|
59,177,643
|
57,370,977
|
59,003,484
|
56,868,585
|
||||||||||||
Diluted
|
65,478,677
|
65,423,232
|
65,772,973
|
65,038,584
|
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
||||||||||||||
(In thousands) |
2022
|
2021
|
2022
|
2021
|
||||||||||||
Single wafer cleaning, Tahoe and semi-critical cleaning equipment
|
$
|
72,583
|
$
|
45,461
|
$
|
98,616
|
$
|
77,874
|
||||||||
ECP (front-end and packaging), furnace and other technologies
|
20,500
|
-
|
32,748
|
5,550
|
||||||||||||
Advanced packaging (excluding ECP), services & spares
|
11,312
|
8,403
|
15,217
|
14,172
|
||||||||||||
Total Revenue By Product Category
|
$
|
104,395
|
$
|
53,864
|
$
|
146,581
|
$
|
97,596
|
||||||||
Wet cleaning and other front-end processing tools
|
$
|
79,553
|
$
|
45,974
|
$
|
111,254
|
$
|
77,874
|
||||||||
Advanced packaging, other processing tools, services and spares
|
24,842
|
7,890
|
35,327
|
19,722
|
||||||||||||
Total Revenue Front-end and Back-End
|
$
|
104,395
|
$
|
53,864
|
$
|
146,581
|
$
|
97,596
|
Three Months Ended June 30,
|
Six Months Ended June 30,
|
|||||||||||||||
2022
|
2021
|
2022
|
2021
|
|||||||||||||
Mainland China
|
$
|
100,275
|
$
|
53,736
|
$
|
142,405
|
$
|
97,432
|
||||||||
Other Regions
|
4,120
|
128
|
4,176
|
164
|
||||||||||||
$
|
104,395
|
$
|
53,864
|
$
|
146,581
|
$
|
97,596
|
Three Months Ended June 30,
|
||||||||||||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||||||||||
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-
GAAP)
|
Actual
(GAAP)
|
SBC
|
Other non-
operating
adjustments
|
Adjusted
(Non-
GAAP)
|
|||||||||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Revenue
|
$
|
104,395
|
$
|
-
|
$
|
-
|
$
|
104,395
|
$
|
53,864
|
$
|
-
|
$
|
-
|
$
|
53,864
|
||||||||||||||||
Cost of revenue
|
(60,238
|
)
|
(140
|
)
|
-
|
(60,098
|
)
|
(32,184
|
)
|
(110
|
)
|
-
|
(32,074
|
)
|
||||||||||||||||||
Gross profit
|
44,157
|
(140
|
)
|
-
|
44,297
|
21,680
|
(110
|
)
|
-
|
21,790
|
||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||
Sales and marketing
|
(7,664
|
)
|
(574
|
)
|
-
|
(7,090
|
)
|
(5,789
|
)
|
(478
|
)
|
-
|
(5,311
|
)
|
||||||||||||||||||
Research and development
|
(11,367
|
)
|
(656
|
)
|
-
|
(10,711
|
)
|
(7,933
|
)
|
(279
|
)
|
-
|
(7,654
|
)
|
||||||||||||||||||
General and administrative
|
(5,091
|
)
|
(599
|
)
|
-
|
(4,492
|
)
|
(3,627
|
)
|
(468
|
)
|
-
|
(3,159
|
)
|
||||||||||||||||||
Income (loss) from operations
|
$
|
20,035
|
$
|
(1,969
|
)
|
$
|
-
|
$
|
22,004
|
$
|
4,331
|
$
|
(1,335
|
)
|
$
|
-
|
$
|
5,666
|
||||||||||||||
Unrealized gain (loss) on trading securities
|
(423
|
)
|
-
|
(423
|
)
|
-
|
3,783
|
-
|
3,783
|
-
|
||||||||||||||||||||||
Net income (loss) attributable to ACM Research, Inc.
|
$
|
12,236
|
$
|
(1,969
|
)
|
$
|
(423
|
)
|
$
|
14,628
|
$
|
6,567
|
$
|
(1,335
|
)
|
$
|
3,783
|
$
|
4,119
|
|||||||||||||
Basic EPS
|
$
|
0.21
|
$
|
0.25
|
$
|
0.11
|
$
|
0.07
|
||||||||||||||||||||||||
Diluted EPS
|
$
|
0.18
|
$
|
0.22
|
$
|
0.10
|
$
|
0.06
|
Six Months Ended June 30,
|
||||||||||||||||||||||||||||||||
2022
|
2021
|
|||||||||||||||||||||||||||||||
Actual
(GAAP)
|
SBC
|
Other non-operating adjustments
|
Adjusted
(Non-
GAAP)
|
Actual
(GAAP)
|
SBC
|
Other non-operating adjustments
|
Adjusted
(Non-
GAAP)
|
|||||||||||||||||||||||||
(In thousands)
|
||||||||||||||||||||||||||||||||
Revenue
|
$
|
146,581
|
$
|
-
|
$
|
-
|
$
|
146,581
|
$
|
97,596
|
$
|
-
|
$
|
-
|
$
|
97,596
|
||||||||||||||||
Cost of revenue
|
(82,738
|
)
|
(253
|
)
|
-
|
(82,485
|
)
|
(57,871
|
)
|
(181
|
)
|
-
|
(57,690
|
)
|
||||||||||||||||||
Gross profit
|
63,843
|
(253
|
)
|
-
|
64,096
|
39,725
|
(181
|
)
|
-
|
39,906
|
||||||||||||||||||||||
Operating expenses:
|
||||||||||||||||||||||||||||||||
Sales and marketing
|
(14,361
|
)
|
(928
|
)
|
-
|
(13,433
|
)
|
(11,097
|
)
|
(983
|
)
|
-
|
(10,114
|
)
|
||||||||||||||||||
Research and development
|
(28,713
|
)
|
(1,067
|
)
|
-
|
(27,646
|
)
|
(13,437
|
)
|
(508
|
)
|
-
|
(12,929
|
)
|
||||||||||||||||||
General and administrative
|
(10,040
|
)
|
(1,095
|
)
|
-
|
(8,945
|
)
|
(7,410
|
)
|
(873
|
)
|
-
|
(6,537
|
)
|
||||||||||||||||||
Income from operations
|
$
|
10,729
|
$
|
(3,343
|
)
|
$
|
-
|
$
|
14,072
|
$
|
7,781
|
$
|
(2,545
|
)
|
$
|
-
|
$
|
10,326
|
||||||||||||||
Unrealized gain (loss) on trading securities
|
(4,281
|
)
|
-
|
(4,281
|
)
|
-
|
2,736
|
-
|
2,736
|
-
|
||||||||||||||||||||||
Net income (loss) attributable to ACM Research, Inc.
|
$
|
6,450
|
$
|
(3,343
|
)
|
$
|
(4,281
|
)
|
$
|
14,074
|
$
|
12,037
|
$
|
(2,545
|
)
|
$
|
2,736
|
$
|
11,846
|
|||||||||||||
Basic EPS
|
$
|
0.11
|
$
|
0.24
|
$
|
0.21
|
$
|
0.21
|
||||||||||||||||||||||||
Diluted EPS
|
$
|
0.10
|
$
|
0.21
|
$
|
0.19
|
$
|
0.18
|
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1680062/000114036122028912/brhc10040384_10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Acm Research, Inc..
Acm Research, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:
Rating
Learn More![]()
We have presented shipments, adjusted EBITDA, free cash flow and adjusted operating income (loss) because they are key measures used by our management and board of directors to understand and evaluate our operating performance, to establish budgets and to develop operational goals for managing our business.
We intend to retain all available funds and any future earnings to support the operation of and to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future.
Research and development expense consists primarily of: compensation of personnel associated with our research and development activities, including stock based compensation; costs of components and other research and development supplies; costs of tools built for product development purposes; travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration; amortization of costs of software used for research and development purposes; and allocated overhead for rent and utilities.
Research and development expense consists primarily of: compensation of personnel associated with our research and development activities, including stock based compensation; costs of components and other research and development supplies; costs of tools built for product development purposes; travel expense associated with the research of technical requirements for product development purposes and testing of concepts under consideration; amortization of costs of software used for research and development purposes; and allocated overhead for rent and utilities.
Shipments, adjusted EBITDA, free cash...Read more
The Lender could, however, assert...Read more
Our cash flow from operating...Read more
We expect that, for the...Read more
We expect that, for the...Read more
Under the Loan Agreement, ACM...Read more
In particular, we believe that...Read more
See "Item 1A, "Risk Factors-...Read more
Our U.S. operation includes sales,...Read more
As a result of the...Read more
Risk Factors-Regulatory Risks-The PRC's currency...Read more
Cash and cash equivalents, short-term...Read more
Research and development expense increased...Read more
Interest income (expense), net, Other...Read more
Interest income (expense), net, Other...Read more
Free Cash Flow The following...Read more
Income Tax Benefit (Expense) The...Read more
The continuation of the COVID-19...Read more
Consistent with our methodology for...Read more
Research and development expense increased...Read more
We have begun to add...Read more
? We define "adjusted EBITDA"...Read more
51 Table of Contents Income...Read more
Our future working capital needs...Read more
Sales and marketing expense consists...Read more
49 Table of Contents Sales...Read more
Other income (expense), net primarily...Read more
Our Independent Registered Public Accounting...Read more
We expect gross margin to...Read more
We expect gross margin to...Read more
Accordingly, we believe that these...Read more
We have shown SAPS technology...Read more
TEBO technology has been developed...Read more
59 Table of Contents Adjusted...Read more
To the extent our cash...Read more
During the six months ended...Read more
Although stock-based compensation is an...Read more
ACM Shanghai was certified as...Read more
ACM Shanghai was certified as...Read more
For the first six months...Read more
43 Table of Contents Comparison...Read more
48 Table of Contents Comparison...Read more
Research and development expense relates...Read more
Research and development expense relates...Read more
Shipments consist of two components:...Read more
The following tables reflect the...Read more
How We Evaluate Our Operations...Read more
Projects: Our strategy includes a...Read more
Fluctuations vary depending on cash...Read more
The increase in our effective...Read more
The increase in our effective...Read more
Our effective tax rate differs...Read more
Our effective tax rate differs...Read more
? Government subsidies related to...Read more
Net Income Attributable to Non-Controlling...Read more
47 Table of Contents Net...Read more
The following summary reflects our...Read more
The increase was driven by...Read more
Other income, net primarily reflects...Read more
42 Table of Contents Recent...Read more
The dollar amount attributed to...Read more
52 Table of Contents Net...Read more
For the six months ended...Read more
The significant change from the...Read more
Consequences of any of those...Read more
The total of buildings and...Read more
Since that time, we have...Read more
Equity income in net income...Read more
Equity income in net income...Read more
Cost of Revenue and Gross...Read more
Cost of Revenue and Gross...Read more
The policies began with an...Read more
55 Table of Contents (b)...Read more
The extent to which COVID-19...Read more
See "Risks Related to International...Read more
The PRC central government may...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Acm Research, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ACMR
CIK: 1680062
Form Type: 10-Q Quarterly Report
Accession Number: 0001140361-22-028912
Submitted to the SEC: Tue Aug 09 2022 4:48:34 PM EST
Accepted by the SEC: Tue Aug 09 2022
Period: Thursday, June 30, 2022
Industry: Special Industry Machinery